within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B03B_VitaminB12AndFolicAcid.B03BA01_Cyanocobalamin;

model Cyanocobalamin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.2166666666666664e-08,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.00102,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0022,
    k12 = 4.333333333333334e-08,
    k21 = 4.333333333333334e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cyanocobalamin</td></tr><tr><td>ATC code:</td><td>B03BA01</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.02</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.13</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cyanocobalamin is a synthetic form of vitamin B12 used to treat and prevent vitamin B12 deficiency. It is essential for DNA synthesis, red blood cell maturation, and neurological function. It is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for adult healthy volunteers after intramuscular and oral administration.</p><h4>References</h4><ol><li><p>Sezer, RG, et al., &amp; Özdemir, GN (2018). Comparison of the efficacy of parenteral and oral treatment for nutritional vitamin B12 deficiency in children. <i>Hematology (Amsterdam, Netherlands)</i> 23(9) 653–657. DOI:<a href=\"https://doi.org/10.1080/10245332.2018.1456023\">10.1080/10245332.2018.1456023</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29577819/\">https://pubmed.ncbi.nlm.nih.gov/29577819</a></p></li><li><p>Mezzano, D, et al., &amp; Leighton, F (2000). Cardiovascular risk factors in vegetarians. Normalization of hyperhomocysteinemia with vitamin B(12) and reduction of platelet aggregation with n-3 fatty acids. <i>Thrombosis research</i> 100(3) 153–160. DOI:<a href=\"https://doi.org/10.1016/s0049-3848(00)00313-3\">10.1016/s0049-3848(00)00313-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11108902/\">https://pubmed.ncbi.nlm.nih.gov/11108902</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B03BA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cyanocobalamin;
